Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Wei

Showing results (361-370 of 786) with videos related to

Pageof 79
Sort By:
Urology|January 11, 2000
Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancerJ T Wei, R L Dunn, M S Litwin, et al.
International Urogynecology Journal and Pelvic Floor Dysfunction|July 10, 2003
Effects of examination technique modifications on pelvic organ prolapse quantification (POP-Q) resultsAnthony G Visco, John T Wei, Leslie Ain McClure, et al.
The Journal of Urology|March 12, 2003
Determinants of long-term sexual health outcome after radical prostatectomy measured by a validated instrumentBrent K Hollenbeck, Rodney L Dunn, John T Wei, et al.
Obstetrics and Gynecology|June 2, 2007
Heterogeneity in anatomic outcome of sacrospinous ligament fixation for prolapse: a systematic reviewDaniel M Morgan, Mary A M Rogers, Markus Huebner, et al.
Life Sciences|January 15, 1977
Opioid properties of beta-lipotropin fragment 60-65, H-Arg-Try-Gly-Gly-Phe-Met-OHP Y Law, E T Wei, L F Tseng, et al.
Journal of the American College of Surgeons|February 3, 2009
Risk factors for prolonged length of stay after urologic surgery: the National Surgical Quality Improvement ProgramLauren P Wallner, Rodney L Dunn, Aruna V Sarma, et al.
Ma Zui Xue Za Zhi = Anaesthesiologica Sinica|June 1, 1990
Intraoperative malignant hyperthermia--report of one caseL H Hu, K F Sit, C R Cheng, et al.
Leukemia & Lymphoma|April 19, 2019
Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutationAlexandra Gomez-Arteaga, Elizabeth Margolskee, Mike T Wei, et al.
Medical Care|March 31, 2009
Physician ownership of ambulatory surgery centers and practice patterns for urological surgery: evidence from the state of FloridaSeth A Strope, Stephanie Daignault, John M Hollingsworth, et al.
Clinical and Experimental Immunology|February 24, 2001
Tears contain the complement regulator CD59 as well as decay-accelerating factor (DAF)E Cocuzzi, L B Szczotka, W G Brodbeck, et al.
Pageof 79

Showing results (361-370 of 786) with videos related to

Sort By:
Pageof 79
Urology|January 11, 2000
Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancerJ T Wei, R L Dunn, M S Litwin, et al.
International Urogynecology Journal and Pelvic Floor Dysfunction|July 10, 2003
Effects of examination technique modifications on pelvic organ prolapse quantification (POP-Q) resultsAnthony G Visco, John T Wei, Leslie Ain McClure, et al.
The Journal of Urology|March 12, 2003
Determinants of long-term sexual health outcome after radical prostatectomy measured by a validated instrumentBrent K Hollenbeck, Rodney L Dunn, John T Wei, et al.
Obstetrics and Gynecology|June 2, 2007
Heterogeneity in anatomic outcome of sacrospinous ligament fixation for prolapse: a systematic reviewDaniel M Morgan, Mary A M Rogers, Markus Huebner, et al.
Life Sciences|January 15, 1977
Opioid properties of beta-lipotropin fragment 60-65, H-Arg-Try-Gly-Gly-Phe-Met-OHP Y Law, E T Wei, L F Tseng, et al.
Journal of the American College of Surgeons|February 3, 2009
Risk factors for prolonged length of stay after urologic surgery: the National Surgical Quality Improvement ProgramLauren P Wallner, Rodney L Dunn, Aruna V Sarma, et al.
Ma Zui Xue Za Zhi = Anaesthesiologica Sinica|June 1, 1990
Intraoperative malignant hyperthermia--report of one caseL H Hu, K F Sit, C R Cheng, et al.
Leukemia & Lymphoma|April 19, 2019
Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutationAlexandra Gomez-Arteaga, Elizabeth Margolskee, Mike T Wei, et al.
Medical Care|March 31, 2009
Physician ownership of ambulatory surgery centers and practice patterns for urological surgery: evidence from the state of FloridaSeth A Strope, Stephanie Daignault, John M Hollingsworth, et al.
Clinical and Experimental Immunology|February 24, 2001
Tears contain the complement regulator CD59 as well as decay-accelerating factor (DAF)E Cocuzzi, L B Szczotka, W G Brodbeck, et al.
Pageof 79